Excited to announce a new paper in @CD_AACR on genetic, biological & therapeutic implications of mutations impacting degradation of RAS proteins in clonal hematopoietic disorders. Led by @_SisiChen and collaboration with @castel_pau and @ColemanLindsley
aacrjournals.org/cancerdiscover… We identify that loss of LZTR1, an adaptor of a Cullin-3 RING E3 ubiquitin ligase complex responsible for degradation of RAS GTPases drive hematopoietic stem cell expansion and leukemia in vivo.

It is a pleasure to announce our publication in @NEJM discovering resistance to non-covalent BTK inhibitors in patients with CLL. A collaborative effort with @anthonymatomd and @TaylorJ_MD led by @ewang2323, Xiaoli Mi, and @MCThompsonMD. nejm.org/doi/full/10.10… Non-covalent BTK inhibitors are promising therapies for CLL patients as they overcome the BTK C481 mutations which cause resistance to covalent BTK inhibitors such as ibrutinib. Previously however, resistance mechanisms to non-covalent BTK inhibitors in patients were unknown.

We are excited to announce our paper in @NatureGenet uncovering a role for minor introns in clonal hematopoietic disorders, Noonan Syndrome, and a diverse number of cancers. A collaboration between our lab (@sloan_kettering) and @bradleybio (@fredhutch): nature.com/articles/s4158… 2.Most eukaryotes have 2 splicing machineries: the major & minor spliceosome. The minor spliceosome recognizes <0.5% of the introns in the human genome. Since their discovery, biological roles for minor introns have been enigmatic.